Aug 28 (Reuters) - VBI Vaccines Inc VBIV.O :
* Says VBI vaccines to present new preclinical data for its GBM immunotherapy, VBI-1901, at Immuno-Oncology Summit
* VBI Vaccines - expects to initiate enrollment in multi-center phase i/2a clinical study evaluating vbi-1901 in patients with recurrent GBM in H2 2017